Université Laval (UL)

University / College


Location: Quebec, Canada (CA) CA

ISNI: 0000000419368390

ROR: https://ror.org/04sjchr03

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Rare germline copy number variants (CNVs) and breast cancer risk (2022) Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, et al. Journal article Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, et al. Journal article Keratose sponges in ancient carbonates – A problem of interpretation (2022) Neuweiler F, Kershaw S, Boulvain F, Matysik M, Sendino C, McMenamin M, Munnecke A Journal article Fundamental Approaches to Robust Differential Beamforming With High Directivity Factors (2022) Huang G, Benesty J, Chen J Journal article On Differential Beamforming with Nonuniform Linear Microphone Arrays (2022) Jin J, Benesty J, Huang G, Chen J Journal article Kronecker Product Multichannel Linear Filtering for Adaptive Weighted Prediction Error-Based Speech Dereverberation (2022) Huang G, Benesty J, Cohen I, Chen J Journal article Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element (2021) Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, Fachal L, et al. Journal article Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases (2021) Bishop JA, Sajed DP, Weinreb I, Dickson BC, Bilodeau EA, Agaimy A, Franchi A, et al. Journal article Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women (2021) Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, et al. Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution